Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma
Background: Stage IV melanoma has a poor prognosis with a median survival of 3-11 months from diagnosis of distant metastases. Response rates in first-line regimens range around 15-20%. Non-responders have a median survival around 6 months. Currently, no second-line treatment in advanced melanoma ha...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
December 08, 2004
|
| In: |
Onkologie
Year: 2004, Volume: 27, Issue: 6, Pages: 540-544 |
| ISSN: | 1423-0240 |
| DOI: | 10.1159/000081335 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000081335 Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/81335 |
| Author Notes: | W. Fink, C. Zimpfer-Rechner, A. Thoelke, R. Figl, M. Kaatz, S. Ugurel, D. Schadendorf |
Search Result 1
Search Result 2
Search Result 3
Search Result 4
Search Result 5
Search Result 6
Search Result 7
Search Result 8
Search Result 9
Search Result 10